Antibody-drug conjugate

Patritumab Deruxtecan for Non-Small Cell Lung Cancer

Atlanta, GA

Phase 3

Waitlist Available

Research Sponsored by Daiichi Sankyo

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Has histologically or cytologically documented metastatic or locally advanced non-squamous NSCLC not amenable to curative surgery or radiation.

Is willing to have a tumor biopsy or provide recently obtained tumor tissue

Must not have

Has a known human immunodeficiency virus (HIV) infection that is not well controlled

Has clinically significant corneal disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline up to approximately 49 months

Awards & highlights

No Placebo-Only Group

Pivotal Trial

Summary

This trial is testing a new drug to see if it's effective and safe for patients with a certain type of lung cancer.

See full description

Who is the study for?

Adults with advanced non-squamous non-small cell lung cancer (NSCLC) that has an EGFR mutation and worsened after EGFR TKI therapy. They should not have had other systemic treatments in the metastatic setting, must be able to perform daily activities with minimal assistance (ECOG PS of 0 or 1), and have adequate organ function.Check my eligibility

What is being tested?

The trial is testing Patritumab Deruxtecan against standard platinum-based chemotherapy in patients whose NSCLC has progressed despite previous treatment with EGFR TKI drugs. The goal is to find a more effective and tolerable treatment for these patients.See study design

What are the potential side effects?

Potential side effects include reactions related to drug infusion, issues affecting blood cells, liver enzymes changes, kidney function alterations, possible lung problems like interstitial lung disease, and general symptoms such as fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My non-squamous NSCLC cannot be cured with surgery or radiation.

show original

Select...

I am willing to undergo a tumor biopsy or provide recent tumor samples.

show original

Select...

My advanced lung cancer cannot be cured with surgery or radiation.

show original

Select...

My cancer progressed despite treatment with a specific lung cancer medication.

show original

Select...

My cancer has a specific EGFR mutation.

show original

Select...

I haven't had any treatments like chemotherapy or immunotherapy for my advanced cancer.

show original

Select...

My blood counts and organ functions are within the required ranges.

show original

Select...

My cancer has a specific EGFR mutation.

show original

Select...

I've had 1 or 2 treatments with specific lung cancer drugs, including a newer type.

show original

Select...

I haven't had any treatments like chemotherapy or immunotherapy for my advanced cancer.

show original

Select...

I am 18 years old or older.

show original

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

show original

Select...

I've had 1 or 2 treatments with specific lung cancer drugs, including a newer type.

show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My HIV infection is not well controlled.

show original

Select...

I have a serious eye condition affecting my cornea.

show original

Select...

I am taking more than 10 mg of prednisone or similar medication daily.

show original

Select...

I have untreated or symptomatic brain or spinal cord tumors needing medication.

show original

Select...

My cancer is confirmed as small cell, mixed small/non-small cell, or squamous non-small cell lung cancer.

show original

Select...

I have or might have a lung condition like ILD or pulmonary fibrosis.

show original

Select...

I have serious heart problems that are not under control.

show original

Select...

I have or had cancer spread to the lining of my brain and spinal cord.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline up to approximately 49 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline up to approximately 49 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to approximately 49 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Based on RECIST v1.1

Secondary study objectives

Clinical Benefit Rate (CBR) as Assessed by BICR and Investigator Review Based on RECIST v1.1

Disease Control Rate (DCR) as Assessed by BICR and Investigator Review Based on RECIST v1.1

Duration of Response (DoR) as Assessed by BICR and Investigator Review Based on RECIST v1.1

+15 more

Side effects data

From 2023 Phase 1 & 2 trial • 182 Patients • NCT02980341

67%

Vomiting

67%

Decreased appetite

67%

Nausea

33%

Atelectasis

33%

Influenza

33%

Upper respiratory tract infection

33%

Melanocytic naevus

33%

Anaemia

33%

Hypokalaemia

33%

Hypoalbuminaemia

33%

Hyperkalaemia

33%

Insomnia

33%

Headache

33%

Peripheral sensory neuropathy

33%

Constipation

33%

Ascites

33%

Rash

33%

Rash maculo-papular

33%

Arthralgia

33%

Oedema

33%

Aspartate aminotransferase increased

33%

Alanine aminotransferase increased

33%

Weight decreased

33%

Blood bilirubin increased

33%

Blood creatinine phosphokinase increased

33%

Blood pressure increased

33%

Fatigue

33%

Dry eye

33%

Pyrexia

100%

80%

60%

40%

20%

Study treatment Arm

Dose Escalation: Cohort 1.6 mg/kg

Dose Escalation: Cohort 3.2 mg/kg

Dose Escalation/Dose Finding: Cohort 4.8 mg/kg

Dose Escalation/Dose Finding: Cohort 6.4 mg/kg

Dose Escalation: Cohort 8.0 mg/kg

Dose Finding: 3.2/4.8/6.4 mg/kg

Dose Finding: 4.2/6.4 mg/kg

Dose Expansion: HER3 High 4.8 mg/kg

Dose Expansion: HER3-High 6.4 mg/kg

Dose Expansion: HER3-Low 6.4 mg/kg

Dose Expansion: TNBC 6.4 mg/kg

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Pivotal Trial

The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Patritumab deruxtecanExperimental Treatment1 Intervention

Participants who will be randomized to receive patritumab deruxtecan (HER3-DXd) 5.6 mg/kg q3W.

Group II: Platinum-based chemotherapyActive Control1 Intervention

Participants who will be randomized to receive platinum-based chemotherapy for 4 cycles: pemetrexed plus either cisplatin or carboplatin. Participants without disease progression after 4 cycles of platinum plus pemetrexed therapy may continue treatment with maintenance pemetrexed with no restriction on the number of cycles.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Patritumab Deruxtecan

2016

Completed Phase 2

~190

0 / 21Eligibility criteria met